newsfilter
← Latest News
GlobeNewswire·

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases and that patients